Eli Lilly Reports P-III Study (LIBRETTO-431) Results of Retevmo (selpercatinib) for Newly-Diagnosed Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Shots:
- The P-III study (LIBRETTO-431) evaluating Retevmo vs Pt-based CT + pemetrexed with/out pembrolizumab in a ratio (2:1) in 261 patients with RET fusion+ advanced or metastatic NSCLC, based on a pre-specified interim efficacy analysis conducted by IDMC
- The study met its 1EPs & showed a significant and clinical improvement in PFS, AEs were generally consistent with those identified across the previously reported Retevmo development program. The results will submit to a peer-reviewed journal and discussed with health authorities
- Retevmo, a highly selective and potent RET kinase inhibitor with CNS activity that may affect both tumor cells and healthy cells resulted in side effects
Ref: Eli lilly | Image: Eli lilly
Related News:- Eli Lilly Reports P-III (SURMOUNT-3 & 4) Studies Results of Tirzepatide for the Treatment of Obesity and Overweight
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
